Enhanced Flu Vaccines in Older Adults: Evidence Differs by Outcome

Key Takeaways
- In adults aged 65 years or older, randomized comparisons of enhanced influenza vaccination found fewer influenza-specific hospitalizations with high-dose than standard-dose vaccine.
- Broader hospitalization and death composites did not consistently show a high-dose advantage.
- mRNA-1010 reduced confirmed influenza illness versus standard dose, but its comparison with high dose measured immune responses rather than clinical efficacy.
- Observational MF59-adjuvanted vaccine evidence suggested benefit versus standard dose, while comparisons with high dose were mixed.
Investigators conducted a systematic review in Viruses of English-language full-text randomized and comparative observational evidence involving adults aged at least 65 years or prespecified older subgroups. Searches of MEDLINE via PubMed and the Cochrane Central Register of Controlled Trials covered January 1995 through August 2026; investigators also screened reference lists and prospectively registered the review in PROSPERO. The 15 included reports comprised five randomized clinical-outcome reports, four randomized immunogenicity and safety reports, and six observational comparative-effectiveness reports. Investigators separately synthesized clinical outcomes, immunogenicity and safety, and observational effectiveness without formal pooling. Comparisons involved high-dose, MF59-adjuvanted, or messenger ribonucleic acid (mRNA)-1010 vaccines against standard dose or another enhanced vaccine. Laboratory-confirmed illness and influenza-specific hospitalization took precedence over code-defined encounters and broad composites.
In randomized high-dose-versus-standard-dose comparisons, GALFLU and DANFLU-2 recorded, respectively, 0.44 and 0.47 fewer influenza-specific hospitalizations per 1000 high-dose recipients. Hospitalizations were identified through health-system records, not routinely confirmed by laboratory testing; DANFLU-2 was conducted in Denmark. Influenza and pneumonia composites were less consistent. FinFluHD's respiratory or cardiovascular hospitalization comparison was imprecise after early termination, while INVESTED found no reduction in its death-or-cardiopulmonary-hospitalization composite among selected patients with cardiovascular risk, including younger adults. That neutral composite neither negates the influenza-specific hospitalization findings nor establishes a mortality benefit.
In the randomized Fluent trial, mRNA-1010 showed efficacy against reverse-transcription polymerase chain reaction (RT-PCR)-confirmed influenza meeting protocol-defined influenza-like illness criteria compared with licensed standard-dose vaccine, both overall and in a prespecified older subgroup. Relative efficacy in participants aged at least 65 years was 27.4%. A separate randomized comparison with high-dose vaccine found stronger day-29 immune responses with mRNA-1010 but assessed no clinical efficacy; solicited reactions were more frequent, whereas unsolicited and serious adverse events were balanced during short follow-up, with no vaccine-related serious adverse events among older adults. In a post hoc Italian hospital test-negative analysis of 512 vaccinated older adults, including 83 laboratory-confirmed cases, MF59-adjuvanted vaccine had 59.2% adjusted relative effectiveness (95% confidence interval, 14.6–80.5%) against laboratory-confirmed severe influenza versus standard dose. Overlapping United States claims analyses from the 2019–2020 season provide North American context, but favored MF59 chiefly for code-defined or outpatient encounters; comparisons with high dose were mixed.
According to the authors, diagnostic codes are less specific than laboratory confirmation, and pneumonia or unrelated cardiopulmonary events may dilute an influenza-related signal in broad composites. FinFluHD's early stop left its comparison imprecise, while INVESTED's selected cardiovascular population limits its relevance to older adults generally. Stronger antibody responses cannot establish clinical efficacy or prevention of severe outcomes. Observational MF59 comparisons remain susceptible to residual confounding and outcome misclassification; the overlapping claims populations do not represent independent replications. Searches limited to two databases and English-language full texts may have missed eligible evidence.
The review authors concluded that randomized evidence against standard dose is clearest for high-dose vaccine on influenza-specific hospitalization. They distinguished mRNA-1010's confirmed-illness efficacy versus standard dose from its immunogenicity evidence, rather than severe-outcome efficacy, versus high dose. With MF59-versus-high-dose effectiveness still uncertain across differing comparators, populations, seasons, designs, and endpoints, the authors found no basis for a universal platform ranking.
Clinician Questions
When did GALFLU and DANFLU-2 start counting influenza-specific hospitalizations after influenza vaccination?
GALFLU and DANFLU-2 began counting influenza-specific hospitalizations 14 days after vaccination in their randomized high-dose-versus-standard-dose influenza vaccine comparisons.
Why did FinFluHD stop before reaching planned enrollment for high-dose influenza vaccine?
FinFluHD, a randomized high-dose-versus-standard-dose influenza vaccine trial among older adults in Finland, ended after the 2019–2020 season because of the COVID-19 pandemic. It recruited less than one-third of its planned sample, contributing to the imprecision of its broad respiratory or cardiovascular hospitalization comparison.
Recommended Reading
- For another influenza vaccine dose comparison in older adults: High-Dose Flu Vaccine Linked to Lower Claims-Defined Dementia Risk
This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.